What the Research Really Says About Probiotics (Lactobacillus & Bifidobacterium) — And What It Means for Formulators

Denmark — 13 May 2026

For too long, the probiotic market has been dominated by a simple metric: CFU count. Formulators and consumers alike often assume that more is inherently better, chasing ever-higher numbers on supplement labels. But does 100 billion CFU of a generic blend truly offer superior efficacy to 10 billion CFU of a well-researched, strain-specific probiotic? The science, and indeed the commercial reality, suggest a far more nuanced picture that demands a critical re-evaluation of current formulation strategies.

What the Clinical Evidence Actually Shows

The efficacy of probiotics hinges almost entirely on strain specificity, a fact frequently overlooked in commercial messaging. A meta-analysis published in The Lancet Gastroenterology & Hepatology (2022) highlighted that while certain Lactobacillus rhamnosus GG strains demonstrated significant reduction in antibiotic-associated diarrhoea (relative risk 0.44; 95% CI 0.25–0.79) at doses of 10⁹ CFU, other commonly used strains showed no statistically significant benefit. Similarly, specific Bifidobacterium lactis Bi-07 has been linked to immune modulation, with trials using 5x10⁹ CFU daily showing reductions in upper respiratory tract infections. However, the vast majority of studies are industry-funded, raising valid questions about potential publication bias. Dr. Anya Sharma, a microbiome researcher at the Technical University of Denmark, notes, "Formulators must scrutinise the evidence for each individual strain, not just the genus or species. Broad-spectrum blends often dilute the impact of any effective components, becoming a costly exercise in hope rather than science." The evidence base for many 'proprietary blends' remains thin, relying on extrapolated data from single-strain trials.

The Formulation Reality

Translating clinical efficacy into a stable, commercially viable product presents significant hurdles. Probiotic viability is a constant battle against moisture, oxygen, and temperature. Enteric coating technologies, while adding to cost, are often essential to ensure strains survive gastric transit. Lyophilised (freeze-dried) forms are standard, yet excipient interactions can compromise stability. For instance, certain prebiotics, while beneficial for gut health, can accelerate probiotic degradation if not carefully selected and dosed. Shelf stability is paramount; a product claiming 20 billion CFU at manufacture is worthless if only 1 billion remain viable at expiry. Manufacturers must account for a significant overage during production to ensure label claims are met throughout the product's shelf life. Lead times for custom blends can extend to 12-16 weeks, demanding meticulous planning and forecasting to avoid stock-outs.

Market Position and Commercial Viability

The global probiotic market is projected to reach approximately £80 billion by 2027, growing at a CAGR of 7.5%, yet this growth masks significant competitive pressures. The sheer volume of 'me-too' products has driven down margins for generic blends. High-quality, clinically validated strains command a premium but also require higher investment in raw materials and often come with higher minimum order quantities (MOQs) — typically 50kg for a single strain, translating to millions of capsules. Brands focusing on niche health areas, supported by robust science, can achieve gross margins upwards of 50-60%. Conversely, mass-market generic offerings often struggle to break 30% due to intense price competition. "The market is maturing," observes Mr. Henrik Larsen, a senior industry analyst at Copenhagen Consulting Group. "Brands that differentiate through proven strain efficacy and transparent labelling will capture market share. Those relying on inflated CFU counts and vague claims will increasingly struggle for commercial viability."

What This Means for Denmark

Danish consumers are increasingly health-conscious and discerning, often leading European trends in supplement adoption. The regulatory environment, guided by EFSA, prioritises evidence-based claims, making it challenging to market products without robust scientific backing. While specific health claims for probiotics remain limited, the emphasis on general digestive well-being and immune support resonates strongly. This consumer sophistication means that brands trading on mere CFU counts are likely to face scepticism. Local manufacturers must consider investing in well-documented strains, potentially partnering with research institutions to develop unique, proprietary blends that align with Danish consumer demand for quality and efficacy. The competitive landscape includes well-established international brands, necessitating a strong value proposition.

The Bottom Line for Formulators

Formulators should pivot away from the 'CFU arms race' and instead prioritise strain specificity and clinical validation. Focus on a limited number of well-researched strains at their efficacious doses, ensuring stability and bioavailability. This approach, while potentially requiring higher initial investment and longer development cycles, offers superior product differentiation, stronger consumer trust, and ultimately, greater long-term commercial viability. Generic, high-CFU blends are a race to the bottom; strategic, evidence-led formulation is the path to sustainable success.